• Sample Page

Targeting the ubiquitin–proteasome system for cancer therapy

FGF9

The IGROVCDDP cisplatin-resistant ovarian cancer cell collection can be resistant to

September 9, 2017 by Katherine Lewis Leave a Comment

The IGROVCDDP cisplatin-resistant ovarian cancer cell collection can be resistant to paclitaxel and choices the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. substrate. Cisplatin level of resistance in IGROVCDDP can be multifactorial and it is mediated partly from the glutathione pathway and reduced build up of medication. Total mobile glutathione had … [Read more…]

Posted in: Blogging Tagged: FGF9, VX-680

XIST RNA paints and induces silencing of one X chromosome LY341495

June 15, 2017 by Katherine Lewis Leave a Comment

XIST RNA paints and induces silencing of one X chromosome LY341495 in mammalian feminine cells providing a robust model to research long-range chromosomal regulation. towards the DAPI-dense Barr Body. Manifestation of do it again LY341495 RNAs may donate to chromosome redesigning and evidence shows that other styles of do it again elements could be involved … [Read more…]

Posted in: Blogging Tagged: FGF9, LY341495

Copyright © 2026 Targeting the ubiquitin–proteasome system for cancer therapy.

Omega Child WordPress Theme by